Proteolysis targeting chimeras (PROTACs) technology has emerged as a novel therapeutic
paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target …

Proteolysis targeting chimera (PROTAC) degradation of pathogenic proteins by hijacking of
the ubiquitin-proteasome-system has become a promising strategy in drug design. The …

Abstract Severe Acute Respiratory Syndrome caused by a coronavirus is a recent viral
infection. There is no scientific evidence or clinical trials to indicate that possible therapies …

Lenalidomide, an immunomodulatory drug (IMiD), is commonly used as a first-line therapy in
many haematological cancers, such as multiple myeloma (MM) and 5q myelodysplastic …

Targeted protein degradation (TPD) by PROTAC (proteolysis-targeting chimera) and
molecular glue small molecules is an emerging therapeutic strategy. To expand the roster of …

Nuclear receptor binding SET domain proteins (NSDs) catalyze the mono-or dimethylation
of histone 3 lysine 36 (H3K36me1 and H3K36me2), using S-adenosyl-l-methionine (SAM) …

Drug development for neurodegenerative diseases such as Alzheimer's disease,
Parkinson's disease, and Huntington's disease has challenging difficulties due to the …

The scientific community has shown considerable interest in proteolysis-targeting chimeras
(PROTACs) in the last decade, indicating their remarkable potential as a means of achieving …

ABSTRACT “A journey of mixed emotions” is a quote that best describes the progress chart
of vascular endothelial growth factor receptor (VEGFR) inhibitors as cancer therapeutics in …

PROteolysis TArgeting Chimeras (PROTACs) are tripartite molecules consisting of a linker
connecting a ligand for a protein of interest to an E3 ligase recruiter, whose rationale relies …